Home › Research › Drug development
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease
Scheltens P, Atri A, Feldman HH, Zetterberg H, Sano M, Johannsen P, Colombo TL, Bardtrum L et al.. Alzheimer's & dementia (New York, N. Y.), 2026-01-10
Topic: Amyloid, tau and blood-test diagnosis
Inclusion criteria are the same for both trials, except that by design, evoke+ also includes participants with significant small vessel pathology. Results Evoke (+) recruited 9996 participants from 566 sites in 40 countries. Both trial populations had similar demographics, and clinical and cognitive baseline characteristics, except that 2.8% of participants in evoke+ had magnetic resonance imaging-documented significant small vessel pathology as per protocol inclusion criteria. Regional-level data demonstrated some differences in AD treatment characteristics, including cholinesterase inhibitor use of 41.7% in North America versus 61.6% in Asia.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Scheltens, P., Atri, A., Feldman, H. H., Zetterberg, H., Sano, M., Johannsen, P., et al. (2026). Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.70200
Vancouver
Scheltens P, Atri A, Feldman HH, Zetterberg H, Sano M, Johannsen P, et al. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2026. doi:10.1002/trc2.70200. PMID: 41522368.
BibTeX
@article{scheltens2026-41522368,
author = {Scheltens, P. and Atri, A. and Feldman, H. H. and Zetterberg, H. and Sano, M. and Johannsen, P. and Colombo, T. L. and Bardtrum, L. and others},
title = {{Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2026},
doi = {10.1002/trc2.70200},
pmid = {41522368},
url = {https://doi.org/10.1002/trc2.70200}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Inclusion criteria are the same for both trials, except that by design, evoke+ also includes participants with significant small vessel pathology.
- Results Evoke (+) recruited 9996 participants from 566 sites in 40 countries.
- Both trial populations had similar demographics, and clinical and cognitive baseline characteristics, except that 2.8% of participants in evoke+ had magnetic resonance imaging-documented significant small vessel pathology as per protocol inclusion criteria.
- Regional-level data demonstrated some differences in AD treatment characteristics, including cholinesterase inhibitor use of 41.7% in North America versus 61.6% in Asia.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants9,996
- Effect size53.0%; 51.9%; 72.8%
- Evidence strengthHigh
How this study scored 74/100
Published in a leading specialty journal. Scored zero for study design because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 43 of the 58 points we could judge it on, which is 74 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 9,996 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41522368) |
| Free to read | 2 / 2 | Free to read |
| Points | 43 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 58 points we could judge it on is 74 out of 100. |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development
Also in Drug development
106 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.